If you’ve been told you have gonorrhea, or you’re trying to figure out why the pill your friend got five years ago isn’t what your clinician is offering today, the ceftriaxone vs cefixime question is the right one to ask. The short answer is that one of them still reliably cures gonorrhea in the United States, and the other one mostly doesn’t anymore. Which is which matters a lot.
Gonorrhea has been quietly outsmarting our antibiotics for decades. Penicillin, tetracycline, ciprofloxacin, azithromycin, the bacterium Neisseria gonorrhoeae has chewed through every one of them. The CDC now classifies it as an urgent antibiotic resistance threat.
So when patients ask which oral pill they can take instead of getting a shot, the honest answer in 2026 is: usually, none. Here’s why.
The Current CDC Recommendation
In 2020, the CDC updated its gonorrhea treatment guideline and made a clean break from the older dual-therapy era. The new standard for uncomplicated gonorrhea of the cervix, urethra, or rectum is a single intramuscular dose of ceftriaxone 500 mg (1 g if the person weighs 150 kg or more). Azithromycin is no longer routinely added unless chlamydia hasn’t been ruled out, in which case doxycycline is preferred.
Cefixime didn’t make the first-line cut. The CDC’s 2021 STI Treatment Guidelines list it only as an alternative when ceftriaxone is genuinely unavailable, and even then with caveats. That’s a big shift from a decade ago, when 400 mg of oral cefixime was an acceptable first-line option.
So in any practical ceftriaxone vs cefixime comparison today, ceftriaxone is the drug that still works dependably. Cefixime is a fallback.
Why Cefixime Lost Its Place
Cefixime is an oral third-generation cephalosporin. On paper, that sounds great, same drug class as ceftriaxone, no injection required. In reality, oral cefixime doesn’t reach the same sustained blood and tissue levels that an intramuscular dose of ceftriaxone does.
That pharmacokinetic gap matters because N. gonorrhoeae has been steadily creeping up its minimum inhibitory concentrations (MICs) to cephalosporins. When the MIC rises, oral cefixime is the first to fail because its peak concentrations are lower. The CDC’s Gonococcal Isolate Surveillance Project has been tracking this drift for years, and it’s the main reason cefixime got demoted.
Treatment failures with cefixime have been reported in Japan, the UK, and parts of Europe, particularly for pharyngeal infections. The throat is an especially hostile site, drug penetration is poor, and that’s where resistant strains tend to emerge first.
Ceftriaxone vs Cefixime: The Quick Comparison
Here’s how the two drugs stack up in practice:
Ceftriaxone (500 mg IM, single dose)
- First-line for all uncomplicated gonorrhea sites (urethral, cervical, rectal, pharyngeal)
- Cure rates above 98% in most US surveillance data
- Requires an injection in a clinic or pharmacy setting
- Generally well tolerated. Injection-site pain is the main complaint
Cefixime (800 mg PO, single dose)
- Alternative only when ceftriaxone can’t be given
- Not recommended for pharyngeal gonorrhea, cure rates there have dropped below acceptable levels
- Convenience of an oral dose, no needle
- Test-of-cure follow-up at 7 to 14 days is recommended if cefixime is used
Notice the dose change. The old 400 mg of cefixime is no longer considered adequate. The current alternative dose is 800 mg, and even then, it’s a compromise.
What About Pharyngeal Gonorrhea?
Throat infections are the toughest to clear and the most common source of silent transmission. If gonorrhea is in the pharynx, cefixime should not be used at all. Ceftriaxone is the only cephalosporin with consistent cure rates above 90% at that site, and even ceftriaxone needs a test-of-cure 7 to 14 days after treatment.
This is the same broader theme you see with other STIs where resistance is shifting under our feet. If you’re curious how this compares for a co-infection that’s frequently treated alongside gonorrhea, our breakdown of azithromycin vs doxycycline for chlamydia walks through why doxycycline took over as the preferred partner drug.
Side Effects and Allergy Considerations
Both drugs are cephalosporins, so the side-effect profiles overlap. Most patients tolerate either one fine. The realistic things to watch for:
- Injection-site soreness or a small bruise with ceftriaxone, lasting a day or two
- Mild GI upset (nausea, loose stools) with cefixime, occasionally with ceftriaxone
- Rash, especially in patients with a history of cephalosporin sensitivity
- Rare but serious allergic reactions in patients with a documented severe penicillin allergy
If you have a true IgE-mediated penicillin allergy (hives, anaphylaxis, swelling), tell your clinician before either drug is given. The CDC has a specific alternative regimen using gentamicin plus oral azithromycin for those situations, described in the MMWR treatment update.
If you’re putting together a travel or household medication supply and wondering what STI-related items make sense to have on hand, our piece on essential medications to pack in an emergency kit gives a useful framework, though prescription antibiotics for gonorrhea should always come through a clinician, not a stockpile.
Cost and Access
A single 500 mg ceftriaxone injection is inexpensive at the wholesale level, but the actual out-of-pocket cost depends on where you get it, a clinic visit, a public health department, or an urgent care all bill differently. Many state and county health departments offer free or low-cost STI treatment, which is worth knowing about.
Cefixime 800 mg as a single oral dose is also reasonably priced as a generic. If your clinician has determined cefixime is appropriate for you, you can compare pharmacy pricing on cefixime at edrugstore.com to see what’s available.
The Bottom Line
In the ceftriaxone vs cefixime decision for gonorrhea in 2026, ceftriaxone is the answer for almost everyone. A single 500 mg intramuscular dose still cures uncomplicated gonorrhea reliably across all anatomical sites. Cefixime remains an option only when ceftriaxone truly isn’t available, and it should never be used for throat infections. Talk to your clinician or pharmacist about which regimen fits your situation, and don’t skip the partner notification and retesting steps, those matter as much as the antibiotic itself.
This article is for informational purposes only and is not medical advice. Always consult a licensed pharmacist or physician before starting, stopping, or changing any medication.
References
- CDC STI Treatment Guidelines, Gonococcal Infections, current first-line and alternative regimens for gonorrhea in adults.
- CDC Antibiotic Resistance Threats Report, classification of drug-resistant N. gonorrhoeae as an urgent threat.
- MMWR: Update to CDC’s Treatment for Gonococcal Infection, 2020, rationale for the move to ceftriaxone monotherapy and dosing change.
- PubMed: Cefixime treatment failures in pharyngeal gonorrhea, early international reports of declining cefixime efficacy.
Dr Steven Schlosser
Dr. Schlosser graduated from Lafayette College Phi Beta Kappa and attended Georgetown Medical School. He had 4 years of medical residency training at Tufts University in Boston in both Gynecology and Internal Medicine. He has had a spotless medical career for the past 40+ years and is Board Certified. Learn More